Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + nab-paclitaxel + carboplatin + Bifidobacterium Triple Viable
- Development stage
- Phase 4
- Lead developer
- Xinyi Pharmaceutical
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is a neoadjuvant regimen being investigated for the treatment of resectable Stage II-IIIB non-small cell lung cancer (NSCLC). It consists of the programmed death-1 (PD-1) immune checkpoint inhibitor nivolumab, a chemotherapy doublet of nab-paclitaxel and carboplatin, and the probiotic BiFico (Bifidobacterium Triple Viable). BiFico is a live biotherapeutic product containing three specific bacterial strains: *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. The rationale for this combination is based on the emerging understanding that the gut microbiota can significantly influence the efficacy of immune checkpoint inhibitors. By modulating the microbiome with BiFico, the regimen aims to enhance systemic anti-tumor immunity and improve the pathological complete response (pCR) rate in patients undergoing surgery for NSCLC.
- Brand names
- OpdivoAbraxaneBiFico
- Other names
- Nivolumab + Chemotherapy + ProbioticsNivolumab + Nab-paclitaxel + Carboplatin + BiFicobifidobacterium trifidum-Xiangya Hospital of Central South University-non-small cell lung cancer
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on nivolumab + nab-paclitaxel + carboplatin + Bifidobacterium Triple Viable.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + nab-paclitaxel + carboplatin + Bifidobacterium Triple Viable.